Association of pulse pressure with clinical outcomes in patients under different antiplatelet strategies after percutaneous coronary intervention: analysis of GLOBAL LEADERS
Can J Cardiol
; 36(5): 747-755, May., 2020. tab., graf.
Artigo
em Inglês
| Sec. Est. Saúde SP, SESSP-IDPCPROD, Sec. Est. Saúde SP
| ID: biblio-1102329
Biblioteca responsável:
BR79.1
Localização: BR79.1
ABSTRACT
BACKGROUND:
We evaluated the association of pulse pressure (PP) and different antiplatelet regimes with clinical and safety outcomes in an all-comers percutaneous coronary intervention (PCI) population.METHODS:
In this analysis of GLOBAL LEADERS (n = 15,936) we compared the experimental therapy of 23 months of ticagrelor after 1 month of dual-antiplatelet therapy (DAPT) vs standard DAPT for 12 months followed by aspirin monotherapy in subjects who underwent PCI and were divided into 2 groups according to the median PP (60 mm Hg). The primary end point (all-cause death or new Q-wave myocardial infarction) and the composite end points patient-oriented composite end points (POCE), Bleeding Academic Research Consortium (BARC) 3 or 5, and net adverse clinical events (NACE) were evaluated.RESULTS:
At 2 years, subjects in the high-PP group (n = 7971) had similar rates of the primary end point (4.3% vs 3.9%; P = 0.058), POCE (14.9% vs 12.7%; P = 0.051), and BARC 3 or 5 (2.5% vs 1.7%; P = 0.355) and higher rates of NACE (16.4% vs 13.7%; P = 0.037) compared with the low-PP group (n = 7965). Among patients with PP < 60 mm Hg, the primary end point (3.4% vs 4.4%, adjusted hazard ratio [aHR] 0.77, 95% confidence interval [CI] 0.61-0.96), POCE (11.8% vs 13.5%, aHR 0.86, 95% CI 0.76-0.98), NACE (12.8% vs 14.7%, aHR 0.85, 95% CI 0.76-0.96), and BARC 3 or 5 (1.4% vs 2.1%, aHR 0.69, 95% CI 0.49-0.97) were lower with ticagrelor monotherapy compared with DAPT. The only significant interaction was for BARC 3 or 5 (P = 0.008).CONCLUSIONS:
After contemporary PCI, subjects with high PP levels experienced high rates of NACE at 2 years. In those with low PP, ticagrelor monotherapy led to a lower risk of bleeding events compared with standard DAPT.
Texto completo:
Disponível
Coleções:
Bases de dados nacionais
/
Brasil
Base de dados:
Sec. Est. Saúde SP
/
SESSP-IDPCPROD
Assunto principal:
Inibidores da Agregação Plaquetária
/
Intervenção Coronária Percutânea
Tipo de estudo:
Fatores de risco
Limite:
Idoso
/
Humanos
Idioma:
Inglês
Revista:
Can J Cardiol
Ano de publicação:
2020
Tipo de documento:
Artigo
Instituição/País de afiliação:
Amsterdam University Medical Centre/hungria
/
Centro Hospitalar Universitário Lisboa Central/PT
/
Core Laboratories/hungria
/
East Lancashire Hospitals NHS Trust/US
/
Erasmus University/hungria
/
Imperial College Royal Brompton Hospital/US
/
Instituto Dante Pazzanese de Cardiologia/BR
/
Jessa Ziekenhuis/BE
/
Medical University of Warsaw/PL
/
National University of Ireland Galway/IE